We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
Sandbox Reserved 390
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
=== '''Human topoisomerase IIbeta in complex with DNA and etoposide''' === | === '''Human topoisomerase IIbeta in complex with DNA and etoposide''' === | ||
<Structure load='3qx3' size='600' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /><!-- PLEASE DO NOT DELETE THIS TEMPLATE --> | <Structure load='3qx3' size='600' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /><!-- PLEASE DO NOT DELETE THIS TEMPLATE --> | ||
| + | |||
| + | ---- | ||
| + | |||
Crystal structure of a large fragment of human type II topoisomerases (TOP2) complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex<ref>PMID: 21778401</ref>. | Crystal structure of a large fragment of human type II topoisomerases (TOP2) complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex<ref>PMID: 21778401</ref>. | ||
Revision as of 17:29, 19 September 2012
Human topoisomerase IIbeta in complex with DNA and etoposide
|
Crystal structure of a large fragment of human type II topoisomerases (TOP2) complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex[1].
The interplay between the , the , and the drug explains the structure-activity relations of etoposide derivatives and the molecular basis of drug-resistant mutations.
Also, at the we can see the , and both , and at the .
References
- ↑ Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011 Jul 22;333(6041):459-62. PMID:21778401 doi:10.1126/science.1204117
